Tesofensine

No. Tesofensine is not FDA-approved for any indication. It was never approved for obesity in the US or EU despite encouraging Phase 2B trial data (Astrup et al., 2008) because of unresolved cardiovascular safety concerns — specifically heart rate and blood pressure elevation at effective doses. The sibutramine precedent (withdrawn globally in 2010 after its SCOUT trial showed increased cardiovascular events) weighs heavily on tesofensine's regulatory status. The drug IS approved in Mexico as Tesomet (combined with metoprolol) for specific narrow indications like Prader-Willi syndrome-associated obesity. In the US market, tesofensine circulates primarily as a 'research chemical' through online suppliers, with no regulatory oversight of quality, dosing, or use. For evidence-based weight loss, Semaglutide, Tirzepatide, and Orforglipron have FDA approval with stronger safety profiles.

Based on the pivotal Phase 2B TIPO-1 trial (24 weeks, 203 obese adults, concurrent hypocaloric diet), mean weight loss was: placebo 2.2%, tesofensine 0.25 mg 6.5%, tesofensine 0.5 mg 11.3%, tesofensine 1.0 mg 12.8% (Astrup et al., 2008). Placebo-adjusted that's roughly 4-11% weight loss depending on dose. These are averages with substantial individual variability. Key caveats: (1) the trial was 24 weeks — longer-term durability data is limited; (2) the data reflects patients in a medically-supervised trial with adherence monitoring, dietary counseling, and real drug (quality-assured). Research chemical users may see different outcomes due to dose variability and lack of lifestyle structure; (3) for comparison, Semaglutide at 68 weeks produces ~15%, Tirzepatide at 72 weeks produces ~20%. Tesofensine's 12-13% at 24 weeks is impressive for the duration but GLP-1 class has surpassed it in absolute magnitude over longer trials.

Because the class history is bad. Sibutramine (Meridia) was a closely related dual monoamine reuptake inhibitor approved in the late 1990s for obesity. It worked — produced roughly 5% placebo-adjusted weight loss. But in 2010, the SCOUT trial (11,000+ patients with cardiovascular risk factors) showed a 16% increased rate of non-fatal MI, non-fatal stroke, and CV death with sibutramine vs placebo, even though the trial excluded patients with the highest CV risk. This led to global withdrawal. Tesofensine's pharmacology overlaps substantially with sibutramine (both are monoamine reuptake inhibitors with appetite suppression mechanism), and tesofensine produces measurable HR elevation (~7 bpm at 1 mg dose) in its trials. Regulators have not been willing to approve tesofensine for broad obesity indication without a comparable CV outcomes trial to establish safety. That trial would need to enroll 10,000+ patients and run 3-5 years; it has not been conducted. Until it is, tesofensine's cardiovascular profile at population level is genuinely unknown.

Completely different mechanisms. Tesofensine is a triple monoamine reuptake inhibitor — it boosts noradrenaline, dopamine, and serotonin in the brain, producing appetite suppression and mild thermogenesis. Semaglutide and Tirzepatide are GLP-1 (and GIP for tirzepatide) receptor agonists — they activate incretin receptors in the hypothalamus and brainstem, producing appetite suppression, delayed gastric emptying, and improved glycemic control. Head-to-head comparisons have not been conducted, but based on separate trials: semaglutide produces ~15% weight loss at 68 weeks, tirzepatide ~20% at 72 weeks, tesofensine ~12-13% at 24 weeks (longer-term tesofensine data limited). GLP-1 class has extensive cardiovascular outcomes trial data showing either neutral or favorable CV effects. Tesofensine has unresolved CV safety. GI side effects are prominent with GLP-1 class (nausea, diarrhea) while tesofensine has stimulant-type side effects (insomnia, dry mouth, palpitations). Injection (GLP-1) vs oral (tesofensine) is another practical difference. For most patients, GLP-1 class should be tried first given the safety profile; tesofensine is a second-line consideration for specific situations.

Tesofensine sold online as a 'research chemical' is typically manufactured in the same overseas labs that produce other research-chemical weight loss products. Quality varies substantially: independent batch testing has shown dose accuracy ranging from ~50% to ~150% of label claim, with contamination and degradation concerns depending on vendor. Legal status in the US: tesofensine is unscheduled federally (not a controlled substance), but it's not an FDA-approved drug, so sale for human consumption is technically illegal. Research chemical vendors use 'not for human consumption' labeling as legal cover. Practical reality: many people consume it, but without the quality controls, dose accuracy, or medical supervision that would apply to an approved pharmaceutical. Risks: (1) unknown dose per capsule means unknown efficacy and unknown risk; (2) no medical oversight for cardiovascular monitoring; (3) no drug-drug interaction screening; (4) no psychiatric screening. If you're considering research chemical tesofensine, at minimum get a batch-level third-party COA (HPLC + mass spec), start at below-label doses, and arrange independent cardiovascular monitoring. Better: pursue regulated alternatives.

Pharmacologically possible — the mechanisms don't overlap — but this combination is not formally studied and has specific concerns. Tesofensine provides monoamine-based appetite suppression with CV side effects. Semaglutide provides GLP-1-based appetite suppression with GI side effects. In theory, additive weight loss is plausible. In practice: (1) combined side effect burden (stimulant + GLP-1 nausea) is taxing; (2) aggressive weight loss exceeds what most patients can handle nutritionally without lean mass loss; (3) cardiovascular monitoring becomes essential — GLP-1 drugs don't amplify tesofensine's CV signal directly but rapid weight loss itself can produce BP/HR changes; (4) drug cost and logistics multiply. If attempted, the reasonable approach: establish stable tesofensine (0.5 mg) for several weeks with clean CV monitoring, then add lowest-dose semaglutide (0.25 mg weekly) with slow titration; never escalate both simultaneously; continuous CV monitoring. In most cases, picking one drug and maximizing it is clinically wiser than dual therapy — Tirzepatide monotherapy at 15 mg achieves ~22% weight loss without tesofensine's CV baggage.

Yes, both. Tesofensine's triple monoamine reuptake inhibition produces stimulant-like cognitive effects similar in character (though not identity) to low-dose ADHD medications: increased alertness, improved concentration, reduced fatigue, mild antidepressant-like mood elevation. In clinical trials, 'quality of life' endpoints favored tesofensine vs placebo, partly because of these effects. The cognitive effects are noticeable within days and sustained during treatment. Downsides: (1) insomnia is common — the long 9-day half-life means even morning dosing produces some evening stimulant exposure; (2) anxiety can emerge or worsen, particularly in patients with underlying anxiety conditions; (3) irritability is reported at higher doses; (4) mania/hypomania risk in patients with bipolar spectrum disorder — this is a significant contraindication. The cognitive profile is often subjectively positive but should not be confused with cognitive enhancement as a primary goal — tesofensine is an obesity drug with cognitive side effects, not a nootropic. If cognitive effects are the primary goal, Modafinil or stimulant medications (methylphenidate, amphetamine) have better evidence bases and lower CV risk profiles for that specific indication.

Because of the 9-day half-life, tesofensine plasma levels decline gradually over 4-6 weeks after the last dose — not acutely. There is no classic withdrawal syndrome: no rebound depression, no acute discontinuation effects, no physical withdrawal symptoms. What does happen: (1) appetite returns gradually as plasma levels drop; (2) weight regain begins and typically accelerates if lifestyle structure isn't in place; (3) heart rate and blood pressure gradually return to baseline; (4) sleep normalizes; (5) any subjective stimulant effects fade. Weight regain after discontinuation is near-universal without sustained behavioral intervention — this is true of virtually all weight loss pharmacology, not tesofensine specifically. Plan for it: (1) establish sustainable dietary patterns during active treatment; (2) maintain resistance training throughout and after; (3) consider bridging to GLP-1 class if long-term pharmacotherapy is clinically indicated; (4) avoid sudden caloric rebound. Drug interaction considerations persist for ~4-6 weeks after discontinuation — do not start MAOIs, serotonergic agents, or other contraindicated drugs immediately after stopping tesofensine.

The honest answer is: evidence for long-term use (>52 weeks) is limited. Published controlled trial data extends primarily to 24 weeks with some 48-week extension data in subsets. Real-world post-marketing data from the Mexican Tesomet approval exists but isn't equivalent to controlled trial evidence. Long-term concerns with tesofensine include: (1) cardiovascular trajectory — the CV signal established in short-term trials could accumulate to clinically meaningful events over years; (2) sympathetic nervous system adaptation and whether sustained HR elevation leads to cardiac remodeling; (3) tolerance development — some patients report need for dose increase at 12-18 months to maintain appetite suppression; (4) psychiatric effects over years of continuous monoamine enhancement; (5) drug-drug interaction management in aging patients who accumulate medications. Realistic long-term strategies: (1) intermittent use (12-16 weeks on, 4-6 weeks off) leverages long half-life for gradual on/off transitions; (2) dose reduction to maintenance levels (0.25 mg) after initial weight loss phase; (3) transition to GLP-1 class for sustained pharmacotherapy; (4) accept weight regain and discontinuation when CV or other concerns emerge. For most patients, tesofensine is best thought of as a 12-24 month intervention in a broader weight management strategy, not a lifetime medication.

Absolute contraindications: (1) Anyone currently on an MAOI or within 14 days of stopping one — hypertensive crisis and serotonin syndrome risk; (2) Recent MI, unstable angina, uncontrolled arrhythmia, or decompensated heart failure — sympathetic activation can be catastrophic; (3) Uncontrolled hypertension (BP persistently >160/100); (4) Pheochromocytoma; (5) Pregnancy — no safety data and concerning class signals; (6) Active substance use disorder with stimulants — additive CV risk and misuse potential; (7) Severe hepatic impairment (Child-Pugh C) or end-stage renal disease — clearance impairment amplifies exposure given already long half-life. Relative contraindications (use only with significant caution and specialist oversight): elderly patients (>65), mild-to-moderate hypertension, arrhythmia history, bipolar disorder (mania risk), severe anxiety disorders, concurrent SSRI/SNRI use, history of seizures, narrow-angle glaucoma. For patients without contraindications but without specific benefit: if you don't have obesity meeting pharmacotherapy indication (BMI ≥30, or ≥27 with comorbidities) and haven't failed or been intolerant of safer alternatives like GLP-1 class, tesofensine is not a reasonable choice. It's not a lifestyle drug or a 'trying to lose 10 pounds for summer' drug — the risk-benefit calculus requires genuine clinical indication.